Beate Schultheis

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations

Medicine, Molecular Biology, Oncology +15

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo et al. · New England Journal of Medicine · 2002 · 631 citations · Full text

Medicine, Hematology, Molecular Genetics +16

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

Letizia Venturini, Karin Battmer, M. Castoldi et al. · Blood · 2007 · 355 citations · Full text

Life Sciences, Molecular Biology, Oncology +9

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

Beate Schultheis, Dirk Strumberg, Ansgar Santel et al. · Journal of Clinical Oncology · 2014 · 257 citations

Medicine, Pharmacology, Pharmacotherapy +17

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

Medicine, Oncology, Pharmacology +16